PURPOSE: To evaluate the long-term efficacy of prostate cancer control and complication rates, in the elderly, after focal therapy with high-intensity focused ultrasound (HIFU). MATERIALS AND METHODS: Between June 1997 and March 2000, patients with localized prostate cancer were included into a focal therapy protocol. Inclusion criteria were: PSA ≤ 10 ng/mL, ≤ 3 positive biopsies with only 1 lobe involved, clinical stage ≤ T2a, Gleason score ≤ 7 (3+4), negative CT scan and bone scan. Hemi-ablation of the prostate was performed with the Ablatherm® device. Survival, complication rates and urinary continence were evaluated. Control biopsies were performed at 1 year. Treatment failure was defined as a positive biopsy or need for salvage therapy. RESULTS: Twelve patients with a mean age 70 years were included. Median follow-up was 10 years. Control prostate biopsies were negative in 11/12 (91%) patients. Overall survival was 83% (10/12) and cancer specific survival was 100% at 10 years. Two patients died from other causes. Recurrence free survival was 90% (95% CI; 0.71-1) at 5 years, and 38% (95% CI; 0.04-0.73) at 10 years. Five patients had salvage therapy with repeat HIFU (n = 1) or hormonal therapy (n = 4) and all salvage patients were alive at 10 years. No patients developed lymph node or bone metastasis. No patients suffered from urinary incontinence. International Prostate Symptom Score was stable at 1 year. Complications included two urinary tract infections and one episode of acute urinary retention. CONCLUSIONS: Hemi-prostate ablation with HIFU can be safely performed in selected elderly patients with adequate long-term cancer control and low complication rates. Results from larger prospective studies using improved imaging techniques and extensive biopsy protocols are awaited.
PURPOSE: To evaluate the long-term efficacy of prostate cancer control and complication rates, in the elderly, after focal therapy with high-intensity focused ultrasound (HIFU). MATERIALS AND METHODS: Between June 1997 and March 2000, patients with localized prostate cancer were included into a focal therapy protocol. Inclusion criteria were: PSA ≤ 10 ng/mL, ≤ 3 positive biopsies with only 1 lobe involved, clinical stage ≤ T2a, Gleason score ≤ 7 (3+4), negative CT scan and bone scan. Hemi-ablation of the prostate was performed with the Ablatherm® device. Survival, complication rates and urinary continence were evaluated. Control biopsies were performed at 1 year. Treatment failure was defined as a positive biopsy or need for salvage therapy. RESULTS: Twelve patients with a mean age 70 years were included. Median follow-up was 10 years. Control prostate biopsies were negative in 11/12 (91%) patients. Overall survival was 83% (10/12) and cancer specific survival was 100% at 10 years. Two patients died from other causes. Recurrence free survival was 90% (95% CI; 0.71-1) at 5 years, and 38% (95% CI; 0.04-0.73) at 10 years. Five patients had salvage therapy with repeat HIFU (n = 1) or hormonal therapy (n = 4) and all salvage patients were alive at 10 years. No patients developed lymph node or bone metastasis. No patients suffered from urinary incontinence. International Prostate Symptom Score was stable at 1 year. Complications included two urinary tract infections and one episode of acute urinary retention. CONCLUSIONS: Hemi-prostate ablation with HIFU can be safely performed in selected elderly patients with adequate long-term cancer control and low complication rates. Results from larger prospective studies using improved imaging techniques and extensive biopsy protocols are awaited.
Authors: R Ganzer; T Franiel; J Köllermann; T Kuru; D Baumunk; A Blana; B Hadaschik; J von Hardenberg; T Henkel; K-U Köhrmann; U-B Liehr; S Machtens; A Roosen; G Salomon; H-P Schlemmer; L Sentker; J Wendler; U Witzsch; M Schostak Journal: Urologe A Date: 2017-10 Impact factor: 0.639
Authors: Ghassan A Barayan; Armen G Aprikian; James Hanley; Wassim Kassouf; Fadi Brimo; Louis R Bégin; Simon Tanguay Journal: World J Urol Date: 2014-11-12 Impact factor: 4.226
Authors: R van Velthoven; F Aoun; Q Marcelis; S Albisinni; M Zanaty; M Lemort; A Peltier; K Limani Journal: Prostate Cancer Prostatic Dis Date: 2015-11-24 Impact factor: 5.554
Authors: Jonathan B Bloom; Samuel A Gold; Graham R Hale; Kareem N Rayn; Vikram K Sabarwal; Ivane Bakhutashvili; Vladimir Valera; Baris Turkbey; Peter A Pinto; Bradford J Wood Journal: Gland Surg Date: 2018-04
Authors: Hashim U Ahmed; Richard G Hindley; Louise Dickinson; Alex Freeman; Alex P Kirkham; Mahua Sahu; Rebecca Scott; Clare Allen; Jan Van der Meulen; Mark Emberton Journal: Lancet Oncol Date: 2012-04-17 Impact factor: 41.316
Authors: Samir S Taneja; James Bennett; Jonathan Coleman; Robert Grubb; Gerald Andriole; Robert E Reiter; Leonard Marks; Abdel-Rahmene Azzouzi; Mark Emberton Journal: J Urol Date: 2016-06-09 Impact factor: 7.450